<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The epidermal growth factor receptor-targeted monoclonal antibody cetuximab (Erbitux) was recently introduced for the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment response is dependent on Kirsten-Ras (K-Ras) mutation status, in which the majority of patients with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-specific K-Ras mutations fail to respond to treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Mutations in the oncogenes B-Raf and PIK3CA (<z:chebi fb="0" ids="16749">phosphoinositide</z:chebi>-3-kinase) may also influence cetuximab response, highlighting the need for a sensitive, accurate and quantitative assessment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> mutation burden </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Mutations in K-Ras, B-Raf and PIK3CA were identified by both dideoxy and quantitative pyrosequencing-based methods in a cohort of unselected <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumours</z:e> (n=102), and pyrosequencing-based mutation calls correlated with various clinico-pathological parameters </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The use of quantitative pyrosequencing-based methods allowed us to report a 13.7% increase in mutation burden, and to identify low-frequency (&lt;30% mutation burden) mutations not routinely detected by dideoxy sequencing </plain></SENT>
<SENT sid="5" pm="."><plain>K-Ras and B-Raf mutations were mutually exclusive and independently associated with a more advanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> phenotype </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Pyrosequencing-based methods facilitate the identification of low-frequency <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> mutations and allow more accurate assessment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> mutation burden </plain></SENT>
<SENT sid="7" pm="."><plain>Quantitative assessment of mutation burden may permit a more detailed evaluation of the role of specific <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> mutations in the pathogenesis and progression of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and may improve future patient selection for targeted drug therapies </plain></SENT>
</text></document>